We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi and Regeneron’s Kevzara Shows No Benefit for Critical COVID-19 Patients
Sanofi and Regeneron’s Kevzara Shows No Benefit for Critical COVID-19 Patients
Sanofi and Regeneron Pharmaceuticals have stopped a phase 3 clinical trial in the U.S. of their rheumatoid arthritis drug Kevzara (sarilumab) as a COVID-19 treatment after it failed to meet its primary endpoints.